To further characterize the effects of the expression and acquired mutations of these proteins in breast cancer subtypes, we utilized the extensive breast cancer database on cBioPortal; in-depth analysis of genetic alteration types by gene demonstrated that DDR1 alterations in breast cancer were predominantly amplifications (2.48%), while the majority of RUNX1 and CBFβ alterations were mutations (2.93% and 3.24%, respectively) (Figure 6A). This evidence concerns the gene RUNX1 and breast carcinoma.